

Special Issue

Ophthalmic Adverse Events following SARS-CoV-2 Vaccination

Message from the Guest Editor

In December 2020, the largest global vaccination efforts were launched to limit the spread and clinical severity of SARS-CoV-2. Although the vaccines have been reported to be highly efficacious in limiting the impact of SARS-CoV-2, their swift development and emergency use authorizations limited the short and long-term evaluation of rare adverse events in real-world settings. Over the past 20 months, several reports and studies have highlighted the adverse events (such as myocarditis, Guillain–Barré syndrome, etc.) following the administration of these vaccines. In this special edition, we are compiling case reports, series, review articles and studies focused on ophthalmic adverse events following SARS-CoV-2 vaccinations.

The submissions may include:

- Case of rare ophthalmic adverse events following vaccination
- Studies reporting risk of ophthalmic adverse events following vaccine
- Analysis of global databases reporting vaccine-associated ophthalmic adverse events
- Review articles evaluating published literature on ocular adverse events with special emphasis on underlying potential mechanisms.

Guest Editor

Dr. Rohan Bir Singh

Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/133575

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).